Contrasting CAMP4 Therapeutics (CAMP) & The Competition

CAMP4 Therapeutics (NASDAQ:CAMP) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare CAMP4 Therapeutics to similar companies based on the strength of its profitability, valuation, institutional ownership, risk, dividends, analyst recommendations and earnings.

Insider & Institutional Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares CAMP4 Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,276.33%	-182.39%	-74.87%
CAMP4 Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Risk & Volatility

CAMP4 Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, CAMP4 Therapeutics’ competitors have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.

Valuation and Earnings

This table compares CAMP4 Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50 million	-$80.40 million	-1.82
CAMP4 Therapeutics Competitors	$702.34 million	$9.48 million	-18.82

CAMP4 Therapeutics’ competitors have higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CAMP4 Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1	1	8	1	2.82
CAMP4 Therapeutics Competitors	9874	15294	45656	1600	2.54

CAMP4 Therapeutics presently has a consensus target price of $10.44, suggesting a potential upside of 168.49%. As a group, “Biotechnology” companies have a potential upside of 126.06%. Given CAMP4 Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe CAMP4 Therapeutics is more favorable than its competitors.

Summary

CAMP4 Therapeutics beats its competitors on 9 of the 13 factors compared.

About CAMP4 Therapeutics

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.